Coya Therapeutics, Inc.
COYA
$4.48
-$0.07-1.54%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 7.94M | 7.95M | 3.99M | 423.50K | 3.69M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 7.94M | 7.95M | 3.99M | 423.50K | 3.69M |
| Cost of Revenue | 15.62M | 16.73M | 13.73M | 13.04M | 13.94M |
| Gross Profit | -7.43M | -8.79M | -9.74M | -12.62M | -10.26M |
| SG&A Expenses | 12.52M | 11.45M | 10.32M | 9.98M | 9.16M |
| Depreciation & Amortization | 23.20K | 27.20K | 27.20K | 27.20K | 27.20K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 28.16M | 28.21M | 24.08M | 23.05M | 23.13M |
| Operating Income | -20.22M | -20.27M | -20.09M | -22.62M | -19.44M |
| Income Before Tax | -21.12M | -21.22M | -19.15M | -21.06M | -17.86M |
| Income Tax Expenses | 3.10K | 3.10K | -720.30K | -720.30K | -720.30K |
| Earnings from Continuing Operations | -21.13 | -21.23 | -18.43 | -20.34 | -17.14 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -21.13M | -21.23M | -18.43M | -20.34M | -17.14M |
| EBIT | -20.22M | -20.27M | -20.09M | -22.62M | -19.44M |
| EBITDA | -20.20M | -20.24M | -20.06M | -22.59M | -19.42M |
| EPS Basic | -1.15 | -1.27 | -1.11 | -1.24 | -1.07 |
| Normalized Basic EPS | -0.63 | -0.71 | -0.70 | -0.80 | -0.70 |
| EPS Diluted | -1.47 | -1.27 | -1.11 | -1.24 | -1.07 |
| Normalized Diluted EPS | -0.63 | -0.71 | -0.70 | -0.80 | -0.70 |
| Average Basic Shares Outstanding | 72.84M | 66.92M | 66.54M | 65.02M | 63.21M |
| Average Diluted Shares Outstanding | 72.84M | 66.92M | 66.54M | 65.02M | 63.21M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |